Selective chemosensitization of rhabdomyosarcoma cell lines following wild-type p53 adenoviral transduction

Anti-Cancer Drugs

Volumn 13, Issue 8, 2002, Pages 881-889

  Shetty, Sheetal ^a   Taylor, Alan C ^a   Harris, Linda C ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Drug sensitivity; p53; pax3 FKHR; Rhabdomyosarcoma

Indexed keywords

ADENOVIRUS VECTOR; BLEOMYCIN; DACTINOMYCIN; FLUOROURACIL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; PROTEIN WTP53; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3; TRANSCRIPTION FACTOR PAX6; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RHABDOMYOSARCOMA; TRANSCRIPTION REGULATION;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENES, P53; HUMANS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; RHABDOMYOSARCOMA; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0036747929     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200209000-00015     Document Type: Article

References (33)

1. Lane DP. p53, Guardian of the genome. Nature 1992; 358: 15-6.
2. Zambetti GP, Levine AJ. A comparison of the biological activities of wild-type and mutant p53. FASEB J 1993; 7: 855-65.
3. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991; 351: 453-5.
4. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-31.
5. Nielsen LL, Maneval DC. p53 tumor suppressor gene therapy for cancer. Cancer Gene Ther 1998; 5: 52-63.
6. Schuler M, Rochlitz C, Horowitz JA, et al. A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum Gene Ther 1998; 9: 2075-82.
7. Swisher SG, Roth JA, Nemunaitis J, et al. Adenovirusmediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 1999; 91: 763-71.
8. Lee JM, Bernstein A. p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 1993; 90: 5742-6.
9. Lowe SW, Ruley HE, Jacks T, Houseman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer drugs. Cell 1993; 74: 957-67.
10. Fan S, El-Diery WS, Bae I, et al. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994; 54: 5824-30.
11. Kohn KW, Jackman J, O'Connor PM. Cell cycle control and cancer chemotherapy. J Cell Biochem 1994; 54: 440-52.
12. Li JH, Lax SA, Kim J, Klamut H, Liu FF. The effects of combining ionizing radiation and adenoviral p53 therapy in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1999; 43: 607-16.
13. Labrecque S, Matlashewski GJ. Viability of wild-type p53-containing and p53 deficent tumor cells following anticancer treatment: the use of human papilloma virus E6 to target p53. Oncogene 1995; 11: 387-92.
14. 1 checkpoint does not decrease cell survival following DNA damage. Cancer Res 1993; 53: 4164-8.
15. Vinyals A, Peinado MA, Gonzalez-Garrigues M, Monzo M, Bonfil RD, Fabra A. Failure of wild-type p53 gene therapy in human cancer cells expressing a mutant p53 protein. Gene Ther 1999; 6: 22-33.
16. Felix CA, Kappel CC, Mitsudomi T, et al. Frequency and diversity of p53 mutations in childhood Rhabdomyosarcoma. Cancer Res 1992; 52: 2243-7.
17. Mulligan LM, Matlashewski GJ, Scrable HJ, Cavenee WK. Mechanisms of p53 loss in human sarcomas. Proc Natl Acad Sci USA 1990; 87: 5863-7.
18. Kusafuka T, Fukuzawa M, Oue T, Komoto Y, Yoneda A, Okada A. Mutation anlaysis of p53 gene in childhood malignant solid tumors. J Pediat Surg 1997; 32: 1175-80.
19. Taylor AC, Shu LL, Danks MK, et al. p53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med Pediat Oncol 2000; 35: 96-103.
20. Pappo AS, Shapiro DN, Crist WM, Maurer HM. Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol 1995; 13: 2123-39.
21. Gibson AA, Harwood FG, Tillman DM, Houghton JA. Selective sensitization to DNA damaging agents in a human rhabdomyosarcoma cell line with inducible wild-type p53 overexpression. Clin Cancer Res 1998; 4: 145-52.
22. Buchman VL, Chumakov PM, Ninkina NN, Samarina OP, Georgiev GP. A variation in the structure of the protein-coding region of the human p53 gene. Gene 1988; 70: 245-52.
23. Clayton J, Pincott JR, van den Berghe JA, Kemshead JT. Comparative studies between a new human rhabdomyosarcoma cell line, JR-1 and its tumor of origin. Br J Cancer 1986; 58: 83-90.
24. Pirollo KF, Hao Z, Rait A, et al. p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene 1997; 14: 1735-46.
25. McPake CR, Tillman DM, Poquette CA, George EO, Houghton JA, Harris LC. Bax is an important determinant of chemosensitivity in pediatric tumor cell lines independent of Bcl-2 expression and p53 status. Oncol Res 1998; 10: 235-44.
26. Shapiro DN, Sublett JE, Li B, Downing JR, Naeve CW. Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. Cancer Res 1993; 53: 5108-12.
27. Chabner BA, Collins JM. Cancer chemotherapy: principles and practice. Philadelphia, PA: Lippincott 1990.
28. Liu L. DNA topoisomerases: topoisomerase-targeting drugs. Adv Pharmacol 1994; 29B: 1-315.
29. Sherr CJ. Tumor surveillance via the ARF-p53 pathway. Genes Dev 1998; 12: 2984-91.
30. Sato N, Mizumoto K, Maehara N, et al. Enhancement of drug-induced apoptosis by antisense oligodeoxynucleotides targeted against Mdm2 and p21WAF1/CIP1. Anticancer Res 2000; 20: 837-42.
31. Conforti G, Nardo T, D'Incalci M, Stefanini M. Proneness to UV-induced apoptosis in human fibroblasts defective in transcription coupled repair is associated with the lack of Mdm2 transactivation. Oncogene 2000; 19: 2714-20.
32. Cocker H, Hobbs S, Tiffin N, Pritchard-Jones K, Pinkerton C, Kelland L. High levels of the MDM2 oncogene in pediatric rhabdomyosarcoma cell lines may confer multidrug resistance. Br J Cancer 2001; 85: 1746-52.
33. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994; 54: 3131-5.